Therapeutic potential of TDT 067 (terbinafine in Transfersome®): A carrier-based dosage form of terbinafine for onychomycosis

Expert Opinion on Investigational Drugs

Volumn 21, Issue 10, 2012, Pages 1549-1562

  Sigurgeirsson, Bárdur ^a   Ghannoum, Mahmoud ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antifungal; Nail; Onychomycosis; TDT 067; Terbinafine; Topical; Transfersome

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIROX; DRUG CARRIER; FLUCONAZOLE; ITRACONAZOLE; NB 002; TAVABOROLE; TDT 067; TERBINAFINE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; BACKACHE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FOOT ULCER; HEADACHE; HUMAN; IONTOPHORESIS; LIPID VESICLE; LIVER DISEASE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NAIL BED; ONYCHOMYCOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SKIN IRRITATION; ULTRASOUND;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DRUG CARRIERS; HUMANS; NAILS; NAPHTHALENES; ONYCHOMYCOSIS;

EID: 84866555259     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.711315     Document Type: Review

References (80)

1. Haneke E. Achilles foot-screening project: background, objectives and design. J Eur Acad Dermatol Venereol 1999;12(Suppl 1):S2-5; discussion S17 (Pubitemid 29417871)
2. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997;133(9):1172-3 (Pubitemid 27408228)
3. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992;126(Suppl 39):23-7
4. Sais G, Jucglà A, Peyŕi J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995;132(5):758-61
5. Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995;133(5):699-703
6. Svejgaard EL, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 2004;47(3-4):131-5 (Pubitemid 38570085)
7. Sigurgeirsson B, Steingŕimsson O, Sveinsdóttir S. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 2002;82(6):467-9 (Pubitemid 36140254)
8. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43(2 Pt 1):244-8 (Pubitemid 30626001)
9. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43(4):641-8
10. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994;31(3 Pt 2):S78-81 (Pubitemid 24280354)
11. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 1999;318(7190):1031-5 (Pubitemid 29191890)
12. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993;29(1):S50-4 (Pubitemid 23197195)
13. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999;141(Suppl 56):26-32
14. Gupta AK. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol 2000;43(4 Suppl):S81-95
15. Joseph W. Are DPMs truly treating onychomycosis. Podiatry Today. 2011. Available from: http://www.podiatrytoday.com/article/3167 [Last accessed 11 November 2011]
16. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007(3):CD001434
17. Elewski BE, Ghannoum MA, Mayser P, et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild to moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active controlled designs. J Eur Acad Dermatol Venereol 2011. [Epub ahead of print]
18. Scher RK, Tavakkol A, Sigurgeirsson B, et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007;56(6):939-44 (Pubitemid 46729696)
19. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994;31(3 Pt 2):S21-5 (Pubitemid 24280342)
20. Boyko EJ, Ahroni JH, Cohen V, et al. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care 2006; 29:1202-7 (Pubitemid 44125910)
21. Roujeau JC, Sigurgeirsson B, Korting HC, et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004;209:301-7 (Pubitemid 39482621)
22. Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38(5 Pt 1):702-4 (Pubitemid 28213713)
23. Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol 1999;12(Suppl 1): S6-9; discussion S17 (Pubitemid 29417872)
24. Sigurgeirsson B, Steingŕimsson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol 2004; 18:48-51 (Pubitemid 38159359)
25. Tosti A, Hay R, Arenas-Guzmán R. Patients at risk of onychomycosis-risk factor identification and active prevention. J Eur Acad Dermatol Venereol 2005;19(Suppl 1):13-16 (Pubitemid 41726924)
26. Saunte DM, Holgersen JB, Haedersdal M, et al. Prevalence of toe nail onychomycosis in diabetic patients. Acta Derm Venereol 2006;86:425-8 (Pubitemid 44450099)
27. Gudnadottir G, Hilmarsdóttir I, Sigurgeirsson B. Onychomycosis in Icelandic swimmers. Acta Derm Venereol 1999;79:376-7 (Pubitemid 29414973)
28. Hilmarsdóttir I, Haraldsson H, Sigurdardottir A, Sigurgeirsson B. Dermatophytes in a swimming pool facility: difference in dermatophyte load in men's and women's dressing rooms. Acta Derm Venereol 2005;85:267-8 (Pubitemid 40695178)
29. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol 2004;50(5):748-52 (Pubitemid 38580554)
30. Kasai T. 1997 Epidemiological survey of dermatophytoses in Japan. Nippon Ishinkin Gakkai Zasshi 2001;42:11-18
31. Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol 2002;138:811-16 (Pubitemid 34625527)
32. Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. Br J Dermatol 1999;141(Suppl 56):5-14
33. Havu V, Heikkila H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol 2000;142:97-102 (Pubitemid 30074477)
34. Gupta AK, Lynch LE, Kogan N, Cooper EA. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 2009;23:256-62
35. Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002;138:353-7 (Pubitemid 34226333)
36. Roberts DT, Taylor WD, Boyle J; British Association of Dermatologists. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-10 (Pubitemid 36461317)
37. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, et al. Taskforce on Onychomycosis Education. Treatment options-development of consensus guidelines. J Eur Acad Dermatol Venereol 2005;19(Suppl 1):25-33 (Pubitemid 41726927)
38. Seebacher C, Brasch J, Abeck D, et al. Onychomycosis. Mycoses. 2007;50:321-7 (Pubitemid 46920268)
39. de Berker D. Clinical practice. Fungal nail disease. N Engl J Med 2009; 360:2108-16
40. Chambers WM, Millar A, Jain S, Burroughs AK. Terbinafine-induced hepatic dysfunction. Eur J Gastroenterol Hepatol 2001;13:1115-18 (Pubitemid 32905209)
41. Tuccori M, Bresci F, Guidi B, et al. Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis. Ann Pharmacother 2008;42(7):1112-17
42. Bansgaard N, Saunte DM, Folkenberg M, Zachariae C. Serious adverse events reporting on systemic terbinafine: a Danish register-based study. Acta Derm Venereol 2011;91(3):358-9
43. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43(4 Suppl):S70-80
44. Gupta AK; Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 2005;4(4):481-5
45. Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007;157(1):149-57 (Pubitemid 46934279)
46. Sigurgeirsson B, Olafsson JH, Steinsson JT, et al. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol 2010;24(8):910-15
47. Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003;149(Suppl 65):5-9 (Pubitemid 37410064)
48. Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv 2008; 5:1267-82
49. Gupta AK, Malkin KF. Ciclopirox nail lacquer and podiatric practice. J Am Podiatr Med Assoc 2000;90(10):502-7
50. Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol 2010;162(1):46-50
51. Nair AB, Chakraborty B, Murthy SN. Effect of polyethylene glycols on the trans-ungual delivery of terbinafine. Curr Drug Deliv 2010;7(5):407-14
52. Ghannoum MA, Long L, Pfister WR. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 2009;52(1):35-43
53. Hui X, Baker SJ, Wester RC, et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 2007;96(10):2622-31 (Pubitemid 47597813)
54. Beutner K, Toledo-Bahena M, Barbosa-Alanis H, et al. Interim results of a multicenter study to evaluate the safety and efficacy of topically applied AN2690 5.0% and 7.5% solutions for the treatment of onychomycosis of the great toenail [abstract no. P1802]. American Academy of Dermatology Annual Meeting; 2007
55. Pannu J, McCarthy A, Martin A, et al. NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans. Antimicrob Agents Chemother 2009;53(8):3273-9
56. Ijzerman M, Baker J Jr, Flack M, Robinson P. Efficacy of topical nanoemulsion (NB-002) for the treatment of distal subungual onychomycosis: a randomized, double-blind, vehicle-controlled trial [abstract no. P2108]. American Academy of Dermatology Annual Meeting; 2010
57. Cevc G. Drug delivery across the skin. Expert Opin Investig Drugs 1997;6:1887-937 (Pubitemid 27517593)
58. Cevc G, Mazgareanu S, Rother M. Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. Int J Pharm 2008;360(1-2):29-39
59. Ghannoum M, Isham N, Henry W, Yurdakul S. Evaluation of the broad-spectrum antimicrobial activity of TDT 067 (terbinafine in Transfersome®) against dermatophytes, yeasts, filamentous fungi, and bacteria [abstract no. 31105]. Infectious Diseases Society of America Annual Meeting; 2011
60. Ghannoum M, Isham N, Henry W, Yurdakul S. Evaluation of the antifungal activity of TDT 067 (terbinafine in Transfersome) in combination with antifungals used in the treatment of systemic fungal infections [abstract no. 31117]. Infectious Diseases Society of America Annual Meeting; 2011
61. Fesq H, Lehmann J, Kontny A, et al. Improved risk-benefit ratio for topical triamcinolone acetonide in transfersome in comparison with equipotent cream and ointment: a randomized controlled trial. Br J Dermatol 2003;149(3):611-19 (Pubitemid 37281596)
62. Benson HA. Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv 2006;3:727-37 (Pubitemid 44781845)
63. Kneer W, Rother I, Rother M, Seidel E; IDEA-033-III-01 Study Group. A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation. Curr Drug Saf 2009;4(1):5-10
64. Rother M, Lavins BJ, Kneer W, et al. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis 2007;66(9):1178-83 (Pubitemid 47309734)
65. Ghannoum MA, Isham N, Herbert J, et al. Activity of TDT 067 (terbinafine in Transfersomes) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentration. J Clin Microbiol 2011;49:1716-20
66. Ghannoum MA, Welshenbaugh A, Imamura Y, et al. Comparison of the in vitro activity of terbinafine and lanoconazole against dermatophytes. Mycoses 2010;53(4):311-13
67. Iorizzo M, Piraccini BM, Tosti A. New fungal nail infections. Curr Opin Infect Dis 2007;20(2):142-5 (Pubitemid 46340795)
68. Gupta AK, Ryder JE, Baran R, Summerbell RC. Non-dermatophyte onychomycosis. Dermatol Clin 2003;21(2):257-68 (Pubitemid 36529759)
69. Dominicus R, Weidner C, Tate H, Kroon H-A. Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome) in patients with onychomycosis. Br J Dermatol 2012;166:1360-2
70. Zaias N, Drachmann D. A method for the determination of drug effectiveness in onychomycosis. J Am Acad Dermatol 1983;9:912-19
71. Yu H-J, Kwon H-M, Oh D-H, Kim JS. Is slow nail growth a risk factor for onychomycosis? Clin Exp Dermatol 2004;29:415-18 (Pubitemid 38980378)
72. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992;17(Suppl 1):41-3
73. Goodfield MJ, Andrew L, Evans EG. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992;304:1151-4
74. van der Schroeff JG, Cirkel PK, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992;126(Suppl 39):36-9
75. Bräutigam M. Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. J Am Acad Dermatol 1998;38:S53-6 (Pubitemid 28215624)
76. Ghannoum M, Isham N, Henry W, et al. Evaluation of the morphological effects of TDT 067 (terbinafine in Tf ®\ransersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo. Antimicrob Agents Chemother 2012;56:2530-4
77. Tschen EH, Jones TM, Kroon H-A. Safety and pharmacokinetics of TDT 067 under conditions of maximal use in onychomycosis of the toenails [abstract no. CARL8-0130]. European Academy of Dermatology and Venereology Spring Symposium; 2011
78. Ghannoum M, Isham N, Henry W, Yurdakul S. Morphological changes in dermatophyte hyphae within nail samples obtained from onychomycosis patients treated with TDT 067 (terbinafine in Transfersome) [abstract no. PO28]. 2011e; 5th Trends in Medical Mycology/European Confederation of Medical Mycology Biannual Meeting; 2011
79. Schatz F, Brautigam M, Dobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995;20(5):377-83 (Pubitemid 26007594)
80. Faergemann J, Zehender H, Boukhabza A, et al. A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication. Acta Derm Venereol 1997;77(1):74-6 (Pubitemid 27067299)